Skip to content

The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function

The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04092439
Acronym
WMJ
Enrollment
18
Registered
2019-09-17
Start date
2019-09-12
Completion date
2020-03-20
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction

Brief summary

The purpose of this study is to test if watermelon juice supplementation improves vascular dysfunction experience during hyperglycemia.

Detailed description

The objective of this pilot study is to determine the potential for watermelon juice to attenuate the reduction postprandial endothelial function and skeletal muscle microvascular blood flow (MVBF) experienced during hyperglycemia. The investigators will attempt to answer the following hypotheses: Hypothesis 1: Watermelon juice supplementation will attenuate the reduction in endothelial dysfunction and microvascular blood flow during an oral glucose challenge. Hypothesis 2: Watermelon juice will increase L-arginine bioavailability during hyperglycemia and correlate with improved vascular response. Exploratory Aim: The postprandial period is defined by increased sympathetic nervous system activity (vasoconstriction) and NO• mediated vasodilation. Heart rate variability (HRV) is a measurement of the balance of parasympathetic to sympathetic activity. The investigators will measure HRV during the oral glucose challenge to interrogate the possibility that watermelon juice can modulate the balance of blood vessel constriction and relaxation during an oral glucose Procedures Involved There will be 1 screening visit, and 2 outpatient visits. Participants will consume watermelon juice or placebo for 2 weeks. The washout period will last 2 weeks prior to the cross-over to the opposite condition. Participants visits will be conducted at the Vascular and Resting Metabolism Lab located in the department of kinesiology at LSU. Screening Visit Participants will undergo consenting and fasting blood draws to measure glucose, lipids, and CBC. Vital signs (blood pressure, body weight, body composition (DXA), heart rate, etc) will be measured. For DXA procedure participants will undergo a whole body scan lasting approximately 10 minutes. Participants will remove all metal objects from their body and lie down on the table. The legs will be secured together using two Velcro straps. The participant will be instructed to remain completely still during the scan. Randomization will be performed to allocate the study participant for their initial group assignment to either the watermelon juice group or placebo. The initial six participants will be assigned treatment A for phase 1 and treatment B for phase 2, thereafter the following 6 will be assigned treatment B first then treatment A. The remaining participant will be randomly assigned either treatment A or B in a counterbalanced fashion. Daily Juice Drop-in visits Since the required supplementation duration is 14 days participants will be provided with 2 days (Saturday and Sunday) worth of watermelon juice or placebo to account for days when the LSU AG Center will not be open. To allow for scheduling conflicts and unforeseen circumstances a 3 day period of supplementation less then or greater than the 14 periods will be permitted. Participants will also be provided with juice or placebo for anticipated instances where they cannot be on campus. In order to monitor compliance participants will be asked return the juice container for the days where juice was consumed off premises. Visit 2 and 3: Oral Glucose Challenge - Postprandial FMD and MVBF Participants will arrive in morning at 6:00am fasted for 10-hours. Body composition will be measured by DXA. Next, participants will rest for 30 minutes in the supine positing while wearing a heart rate monitor (Zephyr, Bioharness) to measure heart rate and heart rate variability. Resting metabolic rate will be measured via indirect calorimetry for 20 minutes. Then fasting measures of blood glucose, FMD (ultrasound) and MVBF (near-infrared spectroscopy) will be taken followed by ingestion of 75 g of glucose (glucola). An IV line will be placed in the participants arm vein for blood draw purposes and will remain there throughout the testing. A blood sample will be drawn, and then the participant will drink a sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after the participant consumes the drink. Each blood sample will be about 1 tablespoon. (6 tablespoons total for the test). During the IV procedure, a small amount of the participant's own blood (less than 1 teaspoon) will immediately be returned into the participants vein through the IV after each specimen is collected. Blood will be drawn at minute 15, 30, 60, 90, 120 minutes. Postprandial measurements of FMD and MVBF will be taken at 30, 60, 90, and 120 minutes.

Interventions

DIETARY_SUPPLEMENTWatermelon Juice

100% Watermelon Juice

Sponsors

Pennington Biomedical Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Capable and willing to give written informed consent and understand inclusion and

Exclusion criteria

. 2. 18-40 years of age 3. BMI between 18-29.9 kg/m2 4. Willing to allow researchers to draw blood and conduct imaging (DXA) for research purposes.

Design outcomes

Primary

MeasureTime frameDescription
Endothelial FunctionTwo weeksFlow mediated dilation

Secondary

MeasureTime frameDescription
Postprandial Blood FlowTwo weeksmicrovascular blood flow

Countries

United States

Participant flow

Participants by arm

ArmCount
Watermelon Juice First, Then Placebo
100% watermelon juice Watermelon Juice: 100% Watermelon Juice
10
Placebo First Then, Watermelon Juice
Fructose matched control Watermelon Juice: 100% Watermelon Juice
8
Total18

Baseline characteristics

CharacteristicWatermelon Juice First, Then PlaceboPlacebo First Then, Watermelon JuiceTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants8 Participants18 Participants
Age, Continuous23.4 years
STANDARD_DEVIATION 2.7
24.2 years
STANDARD_DEVIATION 3.4
23.8 years
STANDARD_DEVIATION 3
Body Mass Index21.9 kg/m2
STANDARD_DEVIATION 1.6
25.0 kg/m2
STANDARD_DEVIATION 3.9
23.3 kg/m2
STANDARD_DEVIATION 3.2
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
10 Participants8 Participants18 Participants
Sex: Female, Male
Female
8 Participants4 Participants12 Participants
Sex: Female, Male
Male
2 Participants4 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 180 / 18
other
Total, other adverse events
0 / 180 / 18
serious
Total, serious adverse events
0 / 180 / 18

Outcome results

Primary

Endothelial Function

Flow mediated dilation

Time frame: Two weeks

Population: Young healthy adults

ArmMeasureValue (MEAN)Dispersion
PlaceboEndothelial Function3.31 millimetersStandard Deviation 0.65
Watermelon JuiceEndothelial Function3.53 millimetersStandard Deviation 0.65
Secondary

Postprandial Blood Flow

microvascular blood flow

Time frame: Two weeks

Population: Young healthy adults

ArmMeasureValue (MEAN)Dispersion
PlaceboPostprandial Blood Flow36.0 100 ml tissue/minStandard Deviation 20.5
Watermelon JuicePostprandial Blood Flow51.0 100 ml tissue/minStandard Deviation 29.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026